Fibrocell Science — Investor Presentation (August 2012)
30 slides from Fibrocell Science's investor presentation, Aug 9, 2012
Slide 1: Fibrocell Science Overview August 2012
Fibrocell Science Overview August 2012
Slide 2: Forward Looking Statement
2 Forward Looking Statement This presentation includes statements that are "forward-looking statements." While management has based any forward-looking statements contained in the presentation on its current expectations, the information on which such expectations were based may change. These forwar
Slide 3: Company Overview: Regenerative Medicine Platform
3 Unique autologous cell therapy company with near-term revenue growth and a broad platform Commercial and development programs utilize a patient's own collagen/elastin producing fibroblast cells to regenerate skin and soft tissues Fibroblast cells decrease with age leading to a breakdown in connect
Slide 4: Unlocking the Power of the Fibroblast
Regenerative Medicine Burn Scars, Acne Scars, Vocal Cord Scarring, Periodontal, Wound Healing Potentially initiates long term, natural tissue healing process Groundbreaking, Validated Platform Regenerates collagen and elastin using a patient's own cells FDA approved, marketed cell therapy product Ex
Slide 5: Fibroblast Overview
5 Fibroblast's key function is to synthesize the extracellular matrix A healthy extracellular matrix prevents wrinkles, fine lines and aging effects Fibroblasts, the 'scaffolding of the skin and soft tissues,' are the only cells that exude collagen The most commonly found cell in connective tissue,
Slide 6: Product Pipeline
Product Pipeline Near-Term Revenue Plus Additional Indications Requiring Small Studies 6 Status Next Steps Aesthetic (Nasolabial Lines and Other) Approved by the FDA in June 2011 for moderate to severe nasolabial fold wrinkles Clinical studies have confirmed treatment is beneficial and safe in other
Slide 7: Platform Drives Rapid Growth
Aesthetics Medical Dermatology Regenerative Medicine Stem Cell Therapy Stem cells differentiate into many types of cells, opening the door to groundbreaking targeted therapies Current use in scientific research ~40,000 people hospitalized each year with severe burns including 25,000 admissions to ho
Slide 8: Manufacturing cost and efficiency improvements
Ongoing experimentation to lower material costs and increase efficiency Rapid test methods Developing a polymerase chain reaction (PCR) test to replace current method for Mycoplasma detection Lower cost, lower cycle time Evaluating alternative growth surface systems Replaces final cell expansion ste
Slide 9: LAVIV Overview
LAVIV Overview
Slide 10: Market Overview for Cosmetic Procedures
10 Any discrepancies in percentage change are due to procedures performed in 1997 that are no longer performed in 2011. Patient base is estimated by dividing the number of procedures by three (assumed number of procedures per patient per year). na = Rankings for this procedure in prior years are not
Slide 11: LAVIV: first personalized aesthetic cell therapy
11 LAVIV is the first and only personalized aesthetic cell therapy for the treatment of nasolabial fold wrinkles Fibroblast platform regenerates collagen cells Effective for fine lines in contrast to toxins and HA products that are indicated for larger lines and do not address the underlying cause E
Slide 12: LAVIV Launch Update
12 Actively train physicians through various personalized programs 772 trained physicians as of June 30, 2012 In order to become a certified LAVIV provider, physicians must receive: a) product education and b) injection technique certification Marketing plan currently consists of outreach at various
Slide 13: Personalized skin creams
13 Premium, personalized skin creams that are derived media used in LAVIV cell expansion and represent novel, high quality moisturizers with broad appeal Personalized Skin Cream (2012 Soft Launch) - derived from an individual's own natural fibroblast cells Fitzpatrick's Cream (2013 Launch) - cream d
Slide 14: Overview of Acne Scarring
14 Acne scarring is the permanent discoloration and/or indentation of the skin as a result of moderate to severe acne Opportunity to capture a large market share No current treatments for acne scars Current treatments for acne scarring are both uncomfortable and ineffective, especially for depressed
Slide 15: Acne scarring Phase II/III study
15 Randomized, multi-center, double-blind, placebo-controlled study in patients with moderate to severe acne 99 subjects received three injections in one cheek and vehicle control (cell culture media) in the other at 14 day intervals Patients evaluated up to four months after the last treatment Succ
Slide 16: Acne Scarring Follow-Up Photos
16 Acne Scarring Follow-Up Photos from Study 25 Month Photos Anecdotally Demonstrate Long-Lasting Effect Time
Slide 17: Restrictive burn scars
17 Autologous fibroblast cell therapy offers functional and aesthetic improvements for burn scar victims Restrictive burn scars are a potential blockbuster indication ~40,000 yearly hospitalizations for severe burns, including 25,000 admissions to hospitals with specialized burn centers (excluding w
Slide 18: Burn Scarring Photos
18 Burn Scarring Photos Effective in High Unmet Medical Need Areas Burn Scars Note: Photos from LAVIV prescribers. Not from clinical studies. Time Case 1 Case 2
Slide 19: Burn Scarring Photos (cont'd)
19 Burn Scarring Photos (cont'd) Effective in High Unmet Medical Need Areas Burn Scars Before 5 Weeks Post Injury 7 Months Post Injury 18 Months Post Injury Area Treated with LAVIV Note: Photos from LAVIV prescribers. Not from clinical studies.
Slide 20: Other Injury Induced Scarring Photos
20 (1) Iraqi war veteran who sustained injuries as a result of shrapnel. Note: Photos from LAVIV prescribers. Not from clinical studies. Time Other Injury Induced(1) Scarring Photos Effective in High Unmet Medical Need Areas
Slide 21: Vocal cord scarring
21 Vocal cord trauma is the most commonly encountered finding in dysphonia (loss of voice) Most often seen after surgery on the vocal folds but can also result from radiation therapy, vocal cold trauma, and idiopathic causes Currently has no effective therapy Positive results in pilot studies Autolo
Slide 22: Interdental papillary insufficiency treatment
22 Treatment of interdental papillary insufficiency with autologous fibroblasts Gum line recession known as "black triangles" between teeth This aesthetic problem may be due to loss of tissue caused by trauma, inflammation or disease There are a few case reports in the periodontal literature describ
Slide 23: Stem Cell Programs
Stem Cell Programs
Slide 24: Mesenchymal stem cell discovery and CIDMOD program
24 Fibrocell has discovered and purified a subset of Mesenchymal stem cells (MSCs) that can differentiate into different, potentially useful cell-types, such as cells that form bone, fat and cartilage The cells can be used for either in vitro research applications or re-implantation back into the do
Slide 25: Stem Cell Collaboration
Stem Cell Collaboration Expansion of Isolated MSCs and IPSCs Background After characterizing UCLA MSC and IPSC dermal fibroblast subpopulations, scientists determined a commercially viable method for maintenance and expansion of the specialized cells is required Fibrocell has entered into a collabor
Slide 26: HOD-MSC spinal fusion platform
Human Osteogenic Dermal Mesenchymal Stem Cell (HOD-MSC) spinal fusion will be a platform to build a strong intellectual property portfolio, using human skin-derived stem cells for a wide variety of indications, such as critical bone loss, osteoarthritis, diabetes, heart disease and Parkinson's Lower
Slide 27: Corporate Overview
Corporate __ Overview
Slide 28: Key Issued and Pending Patents
28 Abbreviated Description of Key Issued and Pending Patents Method for the augmentation of subcutaneous or dermal tissue with autologous dermal fibroblasts Method for the augmentation of subcutaneous or dermal tissue with autologous MSCs Method for the augmentation for vocal cord defects with autol
Slide 29: Executive Management Team
29 Executive Management Team Executive Management Team Executive Management Team Name Position Experience David Pernock Chairman and CEO Served as SVP, Pharmaceuticals, Vaccines (Biologics), Oncology, Acute Care and HIV at GlaxoSmithKline. While at GlaxoSmithKline, David also served in various VP le
Slide 30: Board of Directors and Scientific Advisory Board
30 Board of Directors Board of Directors Board of Directors Board of Directors Board of Directors Name Current Affiliation Name Current Affiliation David Pernock CEO and President, Fibrocell Robert Langer David H. Koch Institute Professor, MIT Declan Daly COO and CFO, Fibrocell Marc Mazur Chairman,
Fibrocell Science — Investor Presentation (August 2012) on 6ix